N/A N=12 Pilot Study of TearCare System - Long-Term Extension
Dry Eye Syndromes
Primary: Mean Change in Tear Break-Up Time From Extension Study Baseline to Month 1 — 12.4 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=101 Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Long Term Follow up Dry Eye Disease
Primary: Number of Participants With the Left Nostril/Abnormal at 6 Months as Assessed by Intranasal Examinations — 0; 0; 0; 0 Participants
Phase 3 N=154 Long Term Administration Study of OPC-12759 Ophthalmic Suspension
Dry Eye Syndromes
Primary: Change From Baseline (CFB) in Fluorescein Corneal Staining (FCS) Score — -2.2; -2.7; -4.1; -4.6 FCS score — p=<0.001
N/A N=200 Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Meibomian Gland Dysfunction · Dry Eye
Primary: Stage 1 Mean Change in Total Meibomian Gland Score From Baseline to 3 Months — 11.6; 4.5 units on a scale — p=<0.0001
Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Phase 3 N=256 Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
Dry Eye Disease (DED)
Primary: Number of Participants With Ocular and Non-ocular Adverse Events — 69; 14; 1; 9 Participants
N/A N=29 Study of the TearCare System in Dry Eye Disease
Dry Eye
Primary: Mean Change in Tear Break-Up Time (TBUT) at 1-month From Baseline — 3.1 seconds
N/A N=26 Mechanisms of Light-based Therapies for Dry Eye Disease
Dry Eye Syndromes · Meibomian Gland Dysfunction
Primary: Change From Baseline in Non-invasive Tear Break Up Time to the Final Follow-up 3 Months After Final Treatment Session — -2.61; -0.85 seconds
N/A N=781 Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Ocular Surface Disease Index (OSDI) Total Score at Baseline — 40.3 Scores on a Scale
N/A N=62 Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
Phase 3 N=350 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
Dry Eye Disease With Severe Keratitis
Primary: The Correlation Between Mean Change From Baseline in Corneal Fluorescein Staining (CFS) Score and Symptom Assessment iN Dry Eye (SANDE) Symptoms Score at Each Visit…
Phase 3 N=236 Trial of CF101 to Treat Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Number of Subjects Who Achieved Complete Clearing of Corneal Staining (i.e., Total Corneal FS Score = 0) at Week 24 — 15; 13; 21; 61 participants
N/A N=57 Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Dry Eye · Dry Eye Syndromes
Primary: Eye Dryness Score — 48 Score on Scale — p=0.0001
Phase 2 N=289 Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
Dry Eye Disease
Primary: Mean Change From Baseline (Week 0) in Visual Analog Scale (VAS) Global Ocular Discomfort Score Over 4 Weeks — 78.3; 76.8; -1.1; -1.7 units on a scale
N/A N=24 DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Neurotrophic Keratitis
Primary: Number/Percentage of Patients Who Achieved Corneal Epithelial Healing at NGF0120 Week 8 (EoT NGF0120=Baseline NGF0122) and Remained Healed at Month 24 and Month 30 of…
N/A N=20 The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability
Dry Eye Syndrome
Primary: Contrast Sensitivity — -0.375; -0.169; -0.313; -0.264 arbitrary units
Phase 3 N=275 A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
Dry Eye Disease
Primary: Ocular Treatment-Emergent Adverse Events by Preferred Term With Incidence Greater Than 2 Percent — 90; 7; 2; 3 adverse event
Phase 3 N=202 CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
Dry Eye Disease (DED)
Primary: Number of Subjects Reporting Any Adverse Events — 97 Participants
Phase 4 N=30 Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax
Dry Eye
Primary: Mean Ocular Surface Staining From Baseline — 0.8; 0.6; 0.5; 0.9 Score on a scale
Phase 3 N=467 Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)
Dry Eye Disease
Primary: Percentage of Subjects Who Achieved Equal to or Greater Than 10 Millimeter Increase From Pre-drop at Baseline to Post-drop on Day 14 in Study Eye Unanesthetized Schirmer…
N/A N=20 Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea
Ocular Rosacea · Dry Eye
Primary: Change in Ocular Surface Disease Index (OSDI) Symptom Survey Score — -25.9; -2.0 percentage of change in OSDI score — p=0.0312
Phase 3 N=535 Dry Eye Assessment and Management Study
Dry Eye
Primary: Mean of Change From Baseline in Ocular Surface Disease Index (OSDI) Score at 6 and 12 Months — -13.9; -12.5 units on a scale — p=0.40
Phase 3 N=465 Study Evaluating the Safety and Efficacy of AR-15512
Dry Eye Disease
Primary: Percentage of Subjects Who Achieved Equal to or Greater Than 10 Millimeter Increase From Pre-drop at Baseline to Post-drop on Day 14 in Study Eye Unanesthetized Schirmer…
N/A N=400 An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy
Dry Eye Syndromes
Primary: Percentage of Patients in Each Category of the Dry Eye Workshop Severity (DEWS) Scale — 65.0; 29.0; 4.2; 1.8 Percentage of Patients
Phase 2 N=102 Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Keratoconjunctivitis Sicca
Primary: Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 — -1.3; -1.7; -1.3 units on a scale — p=0.6199
Phase 4 N=51 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®
Dry Eye Syndromes
Primary: Change From Baseline in the Total Corneal Staining Score With Fluorescein in the Worse Eye — 7.05; -1.51 score on a scale
Phase 3 N=105 Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale
N/A N=34 Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.
Dry Eye
Primary: Change From Baseline in Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Total Score. — -12.6 score on a scale
N/A N=10 Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation
Environmental Exposure
Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2
N/A N=15 Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation
Aqueous Deficient Dry Eye · Meibomium Gland Dysfunction
Primary: Visual Quality — 0.3; 0.32; 0.19; 0.3 microns